Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pharmacodynamic evidence that ciprofloxacin failure against tuberculosis is not due to poor microbial kill but to rapid emergence of resistance.

Antimicrobial agents and chemotherapy - 1 Aug 2005

Gumbo Tawanda, Louie Arnold, Deziel Mark R, Drusano George L

Abstract excerpt

Studies of early bactericidal activity provide a fast and economic way to evaluate the clinical efficacy of potential agents for the treatment of tuberculosis. Based on good early bactericidal activity data, ciprofloxacin entered further studies and is now recommended as part of treatment for multidrug-resistant tuberculosis. We examined the relationship between ciprofloxacin bactericidal activity and the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anti-Infective Agents
Share to Area Under Curve

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Ciprofloxacin

Share to Drug Resistance, Bacterial

Share to Microbial Sensitivity Tests

Share to Mycobacterium tuberculosis

Share to Treatment Failure

Share to Tuberculosis

Source

Open in PubMed Open full text

Identifiers

PMID: 16048921
DOI: 10.1128/AAC.49.8.3178-3181.2005
PMCID: PMC1196238

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pharmacodynamic evidence that ciprofloxacin failure against tuberculosis is not due to poor microbial kill but to rapid emergence of resistance.PMID 16048921Read ↗

Emergence of phenotypic and genotypic antimicrobial resistance in Mycobacterium tuberculosis.Semantic proximity Read ↗

Suppression of ciprofloxacin-induced resistant Pseudomonas aeruginosa in a dynamic kill curve system.Semantic proximity Read ↗

Pharmacodynamic modeling of ciprofloxacin resistance in Staphylococcus aureus.Semantic proximity Read ↗

Temporal interplay between efflux pumps and target mutations in development of antibiotic resistance in Escherichia coli.Semantic proximity Read ↗

Pharmacokinetic/pharmacodynamic model-based combination therapy approach to target antibiotic resistant populations emerged from ciprofloxacin exposure.Semantic proximity Read ↗

A new evolutionary and pharmacokinetic-pharmacodynamic scenario for rapid emergence of resistance to single and multiple anti-tuberculosis drugs.Semantic proximity Read ↗

Bacterial antibiotic resistance studies using in vitro dynamic models: Population analysis vs. susceptibility testing as endpoints of mutant enrichment.Semantic proximity Read ↗

Emergence and selection of isoniazid and rifampin resistance in tuberculosis granulomasSemantic proximity Read ↗

The role of the time-kill kinetics assay as part of a preclinical modeling framework for assessing the activity of anti-tuberculosis drugs.Semantic proximity Read ↗

Use of an in vitro pharmacodynamic model to derive a linezolid regimen that optimizes bacterial kill and prevents emergence of resistance in Bacillus anthracis.Semantic proximity Read ↗

Isoniazid bactericidal activity and resistance emergence: integrating pharmacodynamics and pharmacogenomics to predict efficacy in different ethnic populations.Semantic proximity Read ↗

Efflux-pump-derived multiple drug resistance to ethambutol monotherapy in Mycobacterium tuberculosis and the pharmacokinetics and pharmacodynamics of ethambutol.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.